Randomized Study of Two Dose Levels of Privigen in Pediatric CIDP
Who is this study for? Pediatric patients age 2 to 16 with pediatric chronic inflammatory demyelinating polyneuropathy
What treatments are being studied? IgPro10
Status: Recruiting
Location: See all (9) locations...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
A randomized, open-label, prospective, multicenter study designed to investigate 2 dose levels in pediatric subjects 2 to ≤ 17 years of age with confirmed or possible CIDP, either previously exposed to IVIG treatment or unexposed to IVIG treatment
Eligibility
Participation Requirements
Sex: All
Minimum Age: 2
Maximum Age: 17
Healthy Volunteers: f
View:
• Male or female subjects 2 to ≤ 17 years of age with confirmed or possible CIDP.
Locations
United States
Arizona
Phoenix Children's Hospital
COMPLETED
Phoenix
California
Children's Hospital of Los Angeles
WITHDRAWN
Los Angeles
Iowa
University of Iowa Hospitals and Clinics
WITHDRAWN
Iowa City
Ohio
Akron Children's Hospital
WITHDRAWN
Akron
Pennsylvania
Children's Hospital of Philadelphia
RECRUITING
Philadelphia
Tennessee
Le Bonheur Children's Hospital
WITHDRAWN
Memphis
Texas
Neurology Rare Disease Center
RECRUITING
Denton
Virginia
Children's Specialty Group
COMPLETED
Norfolk
Washington
Seattle Children's Hospital
NOT_YET_RECRUITING
Seattle
Contact Information
Primary
Trial Registration Coordinator
clinicaltrials@cslbehring.com
+1 610-878-4697
Time Frame
Start Date: 2019-02-28
Estimated Completion Date: 2029-12-20
Participants
Target number of participants: 30
Treatments
Experimental: IgPro10 (dose level 1)
Experimental: IgPro10 (dose level 2)
Related Therapeutic Areas
Sponsors
Leads: CSL Behring